Bioactivity of aqueous extracts of Clibadium sylvestre (Aubl.) Baill. and Derris amazonica Killip on the aphid Myzus persicae (Sulzer, 1776) (Hemiptera: Aphididae)

Estudos com inseticidas botânicos vêm ganhando espaço como alternativa no Manejo Integrado de Pragas. Conduziu-se este trabalho com o objetivo de avaliar o efeito de extratos aquosos de folhas e frutos da espécie Clibadium sylvestre, e folhas e raízes da espécie Derris amazonica nas concentrações 0, 1, 2, 4 e 8%, no controle do pulgão Myzus persicae (Hemiptera: Aphididae). Foram conduzidos quatro ensaios, dois testes de preferência sem chance de escolha e dois testes de preferência com chance de escolha, totalizando nove tratamentos com cinco repetições. Foi realizada a triagem fitoquímica das folhas e dos frutos da espécie C. sylvestre e das folhas e das raízes de D. amazonica. As avaliações de mortalidade, número de ninfas e índice de deterrência dos insetos, foram realizadas 24, 48 e 72 horas após a aplicação dos extratos. Os extratos aquosos do fruto do C. sylvestre nas concentrações testadas apresentaram maior mortalidade frente à testemunha, na análise do número de ninfas, o extrato aquoso do fruto do C. sylvestre a 8% apresentou maior eficiência que os demais tratamentos. O extrato da folha de D. amazonica na concentração 1% apresentou maior mortalidade e menor número de ninfas que os demais tratamentos. Os extratos da raiz de D. amazonica aumentaram a mortalidade em todas as concentrações testadas e a concentração 8% da raiz de D. amazonica, apresentou menor número de ninfas. Todos os tratamentos testados apresentaram efeito deterrente. O período de 72 horas foi o que apresentou maior efeito dos extratos, das duas espécies estudadas sobre os insetos.

Conflitos no sul do Brasil e queixa pública contra Alvarenga Peixoto (São João del-Rei, Minas Gerais, 1776-1780)

The objective of this article is to analyze the accounts rendered of the provisions bought by the magistrate Inácio José de Alvarenga Peixoto to serve the soldiers of Minas Gerais state sent to fight in the war against the Spaniards in the south of Brazil.

Anatomia e imagenologia do braço e da coxa da Paca (Cuniculus paca, Linaeus 1776) para determinação do acesso cirúrgico à diáfise do úmero e do fêmur

Pós-graduação em Cirurgia Veterinária - FCAV

Production of human factor VIII-FL in 293T cells using the bicistronic MGMT(P140K)-retroviral vector

Hemophilia A is the most common X-linked bleeding disorder; it is caused by deficiency of coagulation factor VIII (FVIII). Replacement therapy with rFVIII produced from human cell line is a major goal for treating hemophilia patients. We prepared a full-length recombinant FVIII (FVIII-FL), using the pMFG-P140K retroviral vector. The IRES DNA fragment was cloned upstream to the P140K gene, providing a 9.34-kb bicistronic vector. FVIII-FL cDNA was then cloned upstream to IRES, resulting in a 16.6-kb construct. In parallel, an eGFP control vector was generated, resulting in a 10.1-kb construct. The 293T cells were transfected with these constructs, generating the 293T-FVIII-FL/P140K and 293T-eGFP/P140K cell lines. In 293T-FVIII-FL/P140K cells, FVIII and P140K mRNAs levels were 4,410 (+/- 931.7)- and 295,400 (+/- 75,769)-fold higher than in virgin cells. In 293T-eGFP/P140K cells, the eGFP and P140K mRNAs levels were 1,501,000 (+/- 493,700)- and 308,000 (+/- 139,300)-fold higher than in virgin cells. The amount of FVIII-FL was 0.2 IU/mL and 45 ng/mL FVIII cells or 4.4 IU/mu g protein. These data demonstrate the efficacy of the bicistronic retroviral vector expressing FVIII-FL and MGMT(P140K), showing that it could be used for producing the FVIII-FL protein in a human cell line.

Growth hormone receptor polymorphism and growth hormone therapy response in children: a bayesian meta-analysis

Recombinant human growth hormone (rhGH) therapy is used in the long-term treatment of children with growth disorders, but there is considerable treatment response variability. The exon 3-deleted growth hormone receptor polymorphism (GHR(d3)) may account for some of this variability. The authors performed a systematic review (to April 2011), including investigator-only data, to quantify the effects of the GHR(fl-d3) and GHR(d3-d3) genotypes on rhGH therapy response and used a recently established Bayesian inheritance model-free approach to meta-analyze the data. The primary outcome was the 1-year change-in-height standard-deviation score for the 2 genotypes. Eighteen data sets from 12 studies (1,527 children) were included. After several prior assumptions were tested, the most appropriate inheritance model was codominant (posterior probability = 0.93). Compared with noncarriers, carriers had median differences in 1-year change-in-height standard-deviation score of 0.09 (95% credible interval (CrI): 0.01, 0.17) for GHR(fl-d3) and of 0.14 (95% CrI: 0.02, 0.26) for GHR(d3-d3). However, the between-study standard deviation of 0.18 (95% CrI: 0.10, 0.33) was considerable. The authors tested by meta-regression for potential modifiers and found no substantial influence. They conclude that 1) the GHR(d3) polymorphism inheritance is codominant, contrasting with previous reports; 2) GHR(d3) genotypes account for modest increases in rhGH effects in children; and 3) considerable unexplained variability in responsiveness remains.